MOBILion Systems Secures $35 Million in Series B Financial Round

MOBILion delivers high-resolution, high-throughput analysis for the pharmaceutical industry and clinical researchers, improving the characterization of protein-based biotherapeutics and accelerating biomarker discovery

FREMONT, CA: MOBILion Systems, a Chadds Ford, PA-based drug development company, raised $35m in Series B funding. The round was led by aMoon, with participation from Agilent Technologies, IP Group, Hostplus, and Cultivation Capital. In addition to the funding, Todd Sone, Partner at aMoon, joined MOBILion's board.

Led by CEO Melissa Sherman, Ph.D., MOBILion has developed the SLIM technology, which separates, identifies, and analyzes clinically significant molecules, identifying earlier disease detection, improved diagnostic accuracy and treatment options, and reduced healthcare costs. It delivers high-resolution, high-throughput analysis for the pharmaceutical industry and clinical researchers, improving the characterization of protein-based biotherapeutics and accelerating biomarker discovery.

The company intends to use the latest capital to build the commercial team supporting the launch of its first product based on the patented ion mobility separations technology, called Structures for Lossless Ion Manipulation (SLIM), and to expand the development of its product portfolio for pharma QC and diagnostic applications.

"We are very excited to have aMoon join our existing community of investors, who collectively share our vision to advance healthcare and improve how we predict, diagnose, and treat disease by revealing molecules that other instruments leave unseen," MOBILion CEO Melissa Sherman said. "This round of financing will augment our sales and marketing efforts and accelerate the development of second-generation products."

Pharmaceutical customers use SLIM to address deficiencies in the characterization of biologic therapeutics, specifically for glycan analysis, peptide mapping, intact, and subunit protein analysis, which are necessary quality tests that remain difficult or impossible to achieve with existing liquid-chromatography mass spectrometry workflows.

MOBILion's patented product is being employed for glycan characterization of the spike protein that decorates the surface of COVID-19 (SARSCoV2) and its interaction with the host cell receptor angiotensin-converting enzyme 2 (ACE2). The glycan analysis of COVID-19 could help understand how the virus binds to its target and provide researchers with valuable insights that are essential for the development of an effective treatment.

"We share a common vision with MOBILion to develop and commercialize breakthrough technologies that offer unparalleled resolution and speed," said Todd Sone, Partner at aMoon who joins MOBILion's board. "MOBILion is our latest in a series of investments in the 'omics' space, and we look forward to supporting Melissa and her outstanding team as they advance large molecule development and novel biomarker discovery."